Prospektiv Randomiseret Evaluering og Behandling af For tidlig Aterosklerose (PRE-EMPT) (PRE-EMPT)
Prospektiv Randomiseret Evaluering og Behandling af For tidlig Aterosklerose
Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States. This clinical trial will test if screening and early treatment of mild heart disease works.
PRE-EMPT will screen individuals at low 10-year risk of heart disease with heart disease risk factors to identify those who already have early cholesterol build up, also called "plaque", in their heart arteries. It consists of two phases:
-
A Screening Study - Participants will be assessed for plaque by one or both of these scans.
- Coronary Artery Calcium (CAC) Scan: A CT scan that looks for calcium or plaque in heart arteries.
- Coronary CT Angiography (CCTA) Scan: A CT scan that uses contrast dye to create detailed 3D pictures of heart arteries to look for plaque.
-
A Treatment Trial (approximately 1,500 participants) - Based on the results of the CCTA, participants may be randomized into a two-year trial to test medications aimed at reducing or stabilizing plaque. Participants will have a 1 in 4 chance of receiving only placebo, and a 3 in 4 chance of receiving at least one active medication. Participants will take two pills once a day-either both active medications, one active and one placebo, or both placebos.
- Rosuvastatin 20 mg: a cholesterol-lowering medicine
- Colchicine 0.5 mg: a medication that lowers inflammation
Everyone in the trial will be given information and advice on heart-healthy diet and lifestyle.
Participants will have up to two in-person visits for the screening study, then phone visits for the Treatment Trial at the beginning, 3 months, 12 months and 24 months when they will also have an in-person visit for a CCTA Scan. Participants will have blood drawn using an at-home collection device mailed to their home at the beginning, 3 months, and end of the study.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
The PRE-EMPT trial will be a 2x2 factorial, double-masked, placebo-controlled randomized trial of the effects of high-intensity statin and low-dose colchicine, alone and in combination, on CCTA-defined Non-Calcified Coronary Plaque (NCCP) volume at 2 years. Participants found through the screening study with CAC 1-99, or through the known plaque pathway, will be eligible for the trial if they have NCCP without severe stenosis or any other exclusion criteria. Study drug will be delivered directly to participants' homes, lab samples will be self-collected at home, and all study visits will be virtual except the imaging visits (up to 3 over 2 years). The only in-person study activities will be the CAC scan, if applicable, and CCTA at baseline and 2 years. The investigators anticipate that this approach will be attractive to middle-aged, busy individuals who are otherwise healthy and asymptomatic. Importantly, all participants in PRE-EMPT will receive an mHealth lifestyle intervention designed to support behavioral modification, ensuring that all individuals benefit from evidence-based strategies for cardiovascular risk reduction.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Rachel Olson, Project Manager
- Telefonnummer: 919-309-5544
- E-mail: rachel.e.olson@duke.edu
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35205
- Rekruttering
- University of Alabama at Birmingham
-
Ledende efterforsker:
- Kevin Riggs, MD
-
Kontakt:
- Dalton Norwood
- Telefonnummer: 909-786-8315
- E-mail: daltonnorwood@uabmc.edu
-
Mobile, Alabama, Forenede Stater, 36608
- Rekruttering
- Cardiology Associates
-
Kontakt:
- Lynn Ward, RN BSN CCRC
- Telefonnummer: 251-607-9797
- E-mail: lynnward@cardassoc.com
-
Ledende efterforsker:
- Jason Cole, MD
-
-
California
-
Los Angeles, California, Forenede Stater, 90095
- Rekruttering
- University of California, Los Angeles
-
Kontakt:
- Lynae Edmunds
- Telefonnummer: 310--210-9806
- E-mail: laedmunds@mednet.ucla.edu
-
Ledende efterforsker:
- Karol Watson, MD
-
Los Angeles, California, Forenede Stater, 90502
- Rekruttering
- Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
-
Kontakt:
- Sajad Hamal
- Telefonnummer: 310-974-9336
- E-mail: shamal@lundquist.org
-
Ledende efterforsker:
- Matthew Budoff, MD
-
-
Georgia
-
Hiram, Georgia, Forenede Stater, 30141
- Rekruttering
- Wellstar Kennestone Hospital
-
Ledende efterforsker:
- Frank Corrigan, MD
-
Kontakt:
- Frank Corrigan, MD
- Telefonnummer: 678-324-4444
- E-mail: frank.corrigan@wellstar.org
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60637
- Rekruttering
- University of Chicago
-
Ledende efterforsker:
- Tamar Polonsky, MD
-
Kontakt:
- Tamar Polonsky, MD
- Telefonnummer: 773-702-1409
- E-mail: tpolonsky@bsd.uchicago.edu
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21287
- Ikke rekrutterer endnu
- Johns Hopkins University
-
Kontakt:
- Prati Pratishruti, MBBS
- Telefonnummer: 410-301-1245
- E-mail: fpratis1@jhu.edu
-
Ledende efterforsker:
- Michael Blaha, MD
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02114
- Rekruttering
- Massachusetts General Hospital Brigham
-
Kontakt:
- Pearl Lee, MSc
- Telefonnummer: 617-721-7783
- E-mail: plee23@mgh.harvard.edu
-
Ledende efterforsker:
- Michael Honigberg, MD
-
-
Minnesota
-
Duluth, Minnesota, Forenede Stater, 55805
- Rekruttering
- Essentia Health
-
Kontakt:
- Martha Vanderlinde, BS
- Telefonnummer: 218-786-2729
- E-mail: Martha.Vanderlinde@essentiahealth.org
-
Ledende efterforsker:
- Catherine Benzinger, MD
-
-
New York
-
Mount Kisco, New York, Forenede Stater, 10549
- Ikke rekrutterer endnu
- Northern Westchester Hospital
-
Kontakt:
- Dina Katz, MD
- Telefonnummer: 914-762-5810
- E-mail: PRE-EMPT@northwell.edu
-
Ledende efterforsker:
- Dina Katz, MD
-
New York, New York, Forenede Stater, 10021
- Rekruttering
- Weill Cornell Medicine
-
Kontakt:
- Dolores Reynolds, RN
- Telefonnummer: 212-746-4617
- E-mail: dtr2001@med.cornell.edu
-
Ledende efterforsker:
- Sam Kim, MD
-
New York, New York, Forenede Stater, 10016
- Rekruttering
- New York University Langone
-
Ledende efterforsker:
- Harmony Reynolds, MD
-
Kontakt:
- Harmony Reynolds, MD
- Telefonnummer: 212-263-4320
- E-mail: PREEMPT@nyulangone.org
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27710
- Rekruttering
- Duke University Hospital
-
Ledende efterforsker:
- Nishant Shah, MD
-
Kontakt:
- Niki Huffman
- Telefonnummer: 919-681-6458
- E-mail: niki.huffman@duke.edu
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Rekruttering
- Wake Forest University, Advocate Health
-
Ledende efterforsker:
- Michael Shapiro, MD
-
Kontakt:
- Sophia Dawson, BA
- Telefonnummer: 336-713-2338
- E-mail: Sophia.Dawson@advocatehealth.org
-
-
Oregon
-
Portland, Oregon, Forenede Stater, 97239
- Ikke rekrutterer endnu
- Oregon Health and Sciences University
-
Kontakt:
- John Halvorson
- Telefonnummer: 503-418-1679
- E-mail: halvorsj@ohsu.edu
-
Ledende efterforsker:
- Maros Ferencik, MD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19107
- Ikke rekrutterer endnu
- Thomas Jefferson University
-
Kontakt:
- Caroline Freeman, BS
- Telefonnummer: 215-792-3872
- E-mail: Caroline.Freeman@Jefferson.edu
-
Ledende efterforsker:
- Chris Chambers, MD
-
Pittsburgh, Pennsylvania, Forenede Stater, 15213
- Rekruttering
- University of Pittsburgh Medical Center
-
Ledende efterforsker:
- Anum Saeed, MD
-
Kontakt:
- Karli Drewencki
- Telefonnummer: 412-647-2931
- E-mail: drewenckikr2@upmc.edu
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Rekruttering
- Medical University of South Carolina (MUSC)
-
Ledende efterforsker:
- Sheldon Litwin, MD
-
Kontakt:
- Melissa Amitrano, MPH
- Telefonnummer: 843-876-5009
- E-mail: amitrano@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37203
- Ikke rekrutterer endnu
- Vanderbilt University
-
Ledende efterforsker:
- Deepak Gupta, MD
-
Kontakt:
- Gabriella Davies Thoppil, MD MPH
- Telefonnummer: 615-421-1143
- E-mail: g.thoppil@vumc.org
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- Houston Methodist Hospital
-
Kontakt:
- Peyton Martin
- Telefonnummer: 443-413-6350
- E-mail: knasir@houstonmethodist.org
-
Ledende efterforsker:
- Khurrrram Nasir, MD
-
-
Virginia
-
Charlottesville, Virginia, Forenede Stater, 22903
- Rekruttering
- University of Virginia (UVA)
-
Kontakt:
- James Ingersoll
- Telefonnummer: 434-982-1058
- E-mail: WFC5KC@uvahealth.org
-
Ledende efterforsker:
- Todd Villines, MD
-
Fairfax, Virginia, Forenede Stater, 22031
- Ikke rekrutterer endnu
- Inova Health System
-
Kontakt:
- Mahira Awan
- Telefonnummer: 571-472-8570
- E-mail: mahira.awan@inova.org
-
Ledende efterforsker:
- Jared Spitz, MD
-
-
Wisconsin
-
Marshfield, Wisconsin, Forenede Stater, 54449
- Rekruttering
- Marshfield Clinical Research Institute
-
Kontakt:
- Kelly Scheffen
- Telefonnummer: 715-221-7285
- E-mail: preempt@marshfieldresearch.org
-
Ledende efterforsker:
- Jeff VanWormer
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Women aged 40-60 years; Men aged 30-50 years
- Willing and able to provide informed consent and comply with study procedures
- Smart phone user
- Use of highly effective contraception by females with reproductive potential.
- CAC score 1-99 in the screening study or entry through the known plaque pathway (with mild CAC or CAC<100 if known; elevated CAC on baseline CCTA is not exclusionary in the known plaque arm)
- Diagnostic baseline CCTA with NCPV ≥10 mm3 as assessed by the central core lab
Exclusion Criteria:
- Clinical diagnosis of ASCVD including coronary artery disease (CAD), peripheral arterial disease (PAD) or cerebrovascular disease (CeVD)
- Current symptoms thought to be from CAD
- PREVENT ASCVD 10-year risk ≥5% (if known)
- Diabetes Mellitus (DM) as defined by any of the following: DM diagnosis in the medical record or HbA1C of 6.5% or greater. (if known)
- LDL-C ≥190mg/dL (most recent, if known)
- HIV (if known)
- Severe liver disease or untreated Hepatitis C infection (if known)
- Pregnancy, lactation or intending to become pregnant during the study period of 2 years
- eGFR <45mL/min/1.73m2 (if known)
- AST or ALT >1.5x the upper limit of normal (if known)
- BMI>40kg/m2 or unable to have a CCTA scan for any reason
- Allergy to iodinated intravenous contrast or other contraindication to CCTA
- Current or previous use of lipid lowering therapy or colchicine
- Known allergic reactions or sensitivity to the study intervention(s), including known intolerance or contraindication(s) to statin or colchicine, or long-term use of medications that are contraindicated with colchicine or rosuvastatin.
- Systemic cancer undergoing active treatment
- PREVENT ASCVD 10-year risk ≥5%
- eGFR <45 ml/min/1.73m2 per baseline labs, (2021 CKD-EPI equation will be used if multiple options are available)
- Hemoglobin A1c ≥6.5% per baseline labs
- LDL-C ≥190mg/dL per baseline labs
- Severe proximal coronary artery stenosis as determined by the central core lab (≥50% left main or ≥70% proximal major coronary artery stenosis)
- Known contraindication to follow-up CCTA (e.g., new IV contrast allergy discovered during the baseline CCTA)
- Individuals who are excluded based on any of these factors will be notified as to the reason for exclusion and encouraged to follow-up locally to address this medical issue with their treating physician.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Faktoriel opgave
- Maskning: Firedobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: rosuvastatin 20mg plus colchicine-matched placebo
statin plus placebo (two pills once daily) |
Statin
Andre navne:
Placebo, non-active, drug-matched |
|
Eksperimentel: colchicine 0.5mg plus rosuvastatin-matched placebo
anti-inflammatory plus placebo (two pills once daily) |
Placebo, non-active, drug-matched Anti-inflammatory
Andre navne:
|
|
Eksperimentel: rosuvastatin 20mg plus colchicine 0.5mg
statin plus anti-inflammatory (two pills once daily) |
Statin
Andre navne:
Anti-inflammatory
Andre navne:
|
|
Placebo komparator: placebo plus placebo
Placebo and placebo (two pills once daily) |
Placebo, non-active, drug-matched |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Non-calcified plaque volume (NCPV) on CCTA at 2 years, adjusted for baseline NCPV.
Tidsramme: 2 years
|
Plaque volume in mm3 in each group |
2 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Ændring i LDL-C (low-density lipoprotein kolesterol)
Tidsramme: Baseline til 2 år
|
Baseline til 2 år
|
|
|
Ændring i ikke-HDL-kolesterol (high-density lipoprotein kolesterol)
Tidsramme: Baseline til 2 år
|
Baseline til 2 år
|
|
|
Number of participants with Drug Discontinuation
Tidsramme: Up to 2 years
|
Drug Tolerability outcome |
Up to 2 years
|
|
Overall drug treatment adherence
Tidsramme: Up to 2 years
|
Number of days on study drugs |
Up to 2 years
|
|
Safety events of special interest
Tidsramme: Up to 2 years
|
Number of safety events of special interest per group |
Up to 2 years
|
|
Total plaque volume
Tidsramme: Up to 2 years
|
Plaque volume in mm3 per group |
Up to 2 years
|
|
Low-attenuation plaque volume
Tidsramme: Up to 2 years
|
Low attenuated plaque volume in mm3 per group |
Up to 2 years
|
|
Calcified plaque volume
Tidsramme: Up to 2 years
|
Calcified plaque volume in mm3 per group |
Up to 2 years
|
|
Number of participants with stenosis
Tidsramme: Up to 2 years
|
Number of participants with stenosis per group |
Up to 2 years
|
|
Segment involvement score
Tidsramme: Up to 2 years
|
Average score per group |
Up to 2 years
|
|
Number of participants with qualitative calcified, partially calcified and non-calcified plaque composition
Tidsramme: Up to 2 years
|
Number of participants with each plaque composition description per group |
Up to 2 years
|
|
Number of participants with High-risk plaque features (positive remodeling, spotty calcium, napkin ring sign)
Tidsramme: Up to 2 years
|
Number of participants with each plaque feature (high-risk) per group |
Up to 2 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Svovlforbindelser
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Farmaceutiske præparater
- Doseringsformer
- Kulbrinter
- Alkaloider
- Amider
- Pyrimidiner
- Kulbrinter, halogeneret
- Sulfonamider
- Sulfoner
- Fluorobenzener
- Kulbrinter, fluoreret
- Rosuvastatin Calcium
- Colchicin
- Tabletter
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- Pro00118744
- UG3HL181434 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .